Kleberg Foundation Archives
A new mechanism for lupus
Aug. 30, 2022—Vanderbilt researchers describe a new mechanism for the most common form of lupus and suggest a new treatment approach to this autoimmune disease.
Gene network for leukemia factor
Feb. 4, 2021—A new method speeds the analysis of factors that control gene expression from days to minutes, allowing researchers to uncover new targets for cancer treatment.
WIN for blocking cancer growth
Jan. 21, 2021—William Tansey and colleagues identified proteins that interact with the cancer drug target WDR5 and are important for cancer cell growth.
Pancreatic cancer development
Aug. 31, 2017—Elevated levels of the factor G-CSF appear to promote the development of aggressive pancreatic cancer, suggesting a new therapeutic approach for this devastating disease.
HDAC3 role in B-cell development
Aug. 3, 2017—The histone deacetylase HDAC3 is required for the maturation of B cells, white blood cells that produce antibodies.
PET imaging to predict tumor response
Jun. 14, 2017—A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models.
New grants bolster Trauma program’s research initiatives
Feb. 9, 2017—Vanderbilt University Medical Center’s Division of Trauma, Emergency General Surgery and Surgical Critical Care was recently awarded two new research grants.
Kleberg Foundation grant bolsters cancer drug discovery efforts
Aug. 3, 2016—The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation has awarded a $3 million grant to Vanderbilt-Ingram Cancer Center (VICC) investigators in support of VICC’s drug discovery program. The gift awarded over the next three years from the private, San Antonio, Texas-based foundation will enable VICC researchers to pursue the development of new compounds to block the activity of cancer-causing genes and proteins that had previously been considered “undruggable.”
New lead for ovarian cancer treatment
Dec. 10, 2015—Combining inhibitors of the BMP signaling pathway with standard chemotherapy drugs may overcome drug resistance in ovarian cancer.
Growth factor blockade targets breast tumors
Aug. 14, 2014—Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.
PET probe detects dying tumor cells
May. 8, 2014—A novel PET imaging probe detects tumor cell death in vivo and could be useful for personalizing cancer medicine.